Fayer Chronicles Her Journey in Medtech to Improve Women ’s Health

Marissa Fayer, a 20-year medtech executive, entrepreneur, and philanthropist stopped in to speak with MD+DI about the changes she has seen in healthcare and how women have helped shaped the medtech industry. She is the CEO and founder of non-profit HERHealthEQ and the president of advisory firm Fayer Consulting LLC,. MD+DI: You’ve made a tremendous impact in the healthcare industry – but tell me what led you to this field? Also, when you started your career how did the landscape in the profession look? Was it particularly diverse? How has it changed since you first started? You’ve worked with some pretty big players in the industry. Fayer: I have always been in the Medtech and medical device industry my entire career. I was recruited by a company right after university and never looked back. The industry is always growing, innovating, and changing which I felt was interesting. I also saw the impact of being able to help improve people’s lives in an indirect but meaningful way. The industry has certainly changed a lot, for the better. Healthcare generally does skew towards a more female-focused environment, but that wasn’t necessarily the case in the manufacturing and operations side of the business in a Medtech company. I knew I was always going to be among a small group of women, which was both hard and motivating at the same time. Over the past 20 years, it has changed sign...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news

Related Links:

Publication date: Available online 21 November 2019Source: Journal of Acupuncture and Meridian StudiesAuthor(s): Maria P. Volpato, Izabela C.A. Breda, Ravena C. de Carvalho, Caroline de Castro Moura, Laís L. Ferreira, Marcelo L. Silva, Josie R.T. Silva
Source: Journal of Acupuncture and Meridian Studies - Category: Complementary Medicine Source Type: research
Publication date: Available online 6 April 2020Source: Indian Heart JournalAuthor(s): Samit Ghosal, Binayak Sinha, Jignesh Ved, Mansij Biswas
Source: Indian Heart Journal - Category: Cardiology Source Type: research
Purpose of review Hyperlipidemia, hypertension, diabetes and related metabolic disorders increase the risk for cardiovascular disease (CVD). Despite significant progress in the identification of key mechanisms and genetic polymorphisms linked to various CVDs, the rates of CVDs continue to escalate, underscoring the need to evaluate additional mechanisms for more effective therapies. Environment and lifestyle changes can alter epigenetic mechanisms mediated by histone modifications and long noncoding RNAs (lncRNAs) which play important roles in gene regulation. The review summarizes recent findings on the role of epigenet...
Source: Current Opinion in Cardiology - Category: Cardiology Tags: MOLECULAR GENETICS: Edited by Ali J. Marian Source Type: research
Purpose of review Orthotopic heart transplantation (OHT) significantly improves morbidity and mortality in patients with end-stage heart disease. Despite advances in surgical technique, immunosuppressive therapies, and patient monitoring, long-term risk of arrhythmias and sudden cardiac death (SCD) in the denervated heart remains unchanged. Recent findings SCD is responsible for approximately 10% of all posttransplant deaths with a pooled incidence rate of 1.30 per 100 person years and is strongly associated with cardiac allograft vasculopathy (CAV). Risk factors for SCD and CAV include higher donor age, younger recip...
Source: Current Opinion in Cardiology - Category: Cardiology Tags: CARDIAC FAILURE: Edited by Rebecca Cogswell and Gene Kim Source Type: research
We present recent series examining sequencing of approved therapies while searching for predictive biomarkers. Finally, we examine trials evaluating novel agents that target certain biological pathways to highlight the likely future directions for progress in the clinical management of advanced prostate cancer.
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research
Purpose of review The present article highlights the most common DNA repair gene mutations, using specific examples of individual genes or gene classes, and reviews the epidemiology and treatment implications for each one [with particular emphasis on poly-ADP-ribose polymerase (PARP) inhibition and PD-1 blockade]. Recent findings Genetic and genomic testing have an increasingly important role in the oncology clinic. For patients with prostate cancer, germline genetic testing is now recommended for all men with high-risk and metastatic disease, and somatic multigene tumor testing is recommended for men with metastatic ...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research
Purpose of review The present review describes the current role of metabolic imaging techniques such as multiparametric MRI (mpMRI), magnetic resonance spectroscopic imaging (MRSI), hyperpolarized MRSI, and positron emission tomography (PET) in the diagnosis of primary prostate cancer, surveillance of low-grade disease, detection of metastases, and evaluation of biochemical recurrence after therapy. Recent findings The natural history of prostate cancer ranges from indolent disease that is optimally monitored by active surveillance, to highly aggressive disease that can be lethal. Current diagnostic methods remain imp...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research
Purpose of review Urothelial carcinoma is one of the 10 most common forms of cancer in the world with more than half a million cases diagnosed yearly. The past few years have witnessed a revolution in understanding the biology of urothelial carcinoma and the development of promising therapies. In this review, we summarize the emerging therapeutic approaches in the management of advanced urothelial carcinoma. Recent findings Since 2016, the Food and Drug Administration (FDA) has approved five checkpoint inhibitors (CPIs), a fibroblast growth factor receptor (FGFR) inhibitor, and an antibody drug conjugate (ADC) for the...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research
Purpose of review Although testicular cancer remains a highly curable malignancy, challenges and uncertainty still remain in certain aspects of management. Residual disease after chemotherapy in patients with germ cell tumors (GCT) remains one of these challenges. We aim to highlight the recent literature on the management of residual disease after chemotherapy in GCT and the emerging innovations that may provide further guidance into this area. Recent findings A subset of patients with GCT will have residual disease after chemotherapy, and management of these patients involves highly skilled multidisciplinary experts...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research
No abstract available
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: HEAD AND NECK: Edited by Joël Guigay Source Type: research
More News: Babies | Babies Heart Conditions | Back Pain | Burns | Cancer | Cancer & Oncology | Cardiology | Children | Costa Rica Health | Diabetes | Education | Employment | Endocrinology | Environmental Health | Heart | Heart Disease | Hospitals | Legislation | Medical Devices | Pain | Pain Management | Parenting | Politics | Universities & Medical Training | Women